Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

@article{Eichhorn2008Phosphatidylinositol3H,
  title={Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.},
  author={Pieter Johan Adam Eichhorn and Mag{\"u}i Gili and Maurizio Scaltriti and Violeta Serra and Marta Guzm{\'a}n and Wouter Nijkamp and Roderick L. Beijersbergen and Vanesa Valero and Joan Seoane and Ren{\'e} Bernards and Jos{\'e} Baselga},
  journal={Cancer research},
  year={2008},
  volume={68 22},
  pages={
          9221-30
        }
}

• Pieter Johan Adam Eichhorn, Magüi Gili, +8 authors José Baselga
• Published in Cancer research 2008
• DOI:10.1158/0008-5472.CAN-08-1740

Small molecule inhibitors of HER2 are clinically active in women with advanced HER2-positive breast cancer who have progressed on trastuzumab treatment. However, the effectiveness of this class of agents is limited by either primary resistance or acquired resistance. Using an unbiased genetic approach, we performed a genome wide loss-of-function short hairpin RNA screen to identify novel modulators of resistance to lapatinib, a recently approved anti-HER2 tyrosine kinase inhibitor. Here, we… CONTINUE READING

View PDF

Save to Library

Create Alert

Cite